Moore Capital Management, LP Fate Therapeutics Inc Transaction History

Moore Capital Management, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$21.04 - $36.06 $631,052 - $1.08 Million	29,993 New	29,993 $672,000
Q2 2022 Aug 15, 2022	SELL	$17.78 - $42.39 $407,926 - $972,553	-22,943 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$29.67 - $60.28 $680,718 - $1.38 Million	22,943 New	22,943 $890,000
Q3 2021 Nov 15, 2021	SELL	$59.27 - $95.73 $1.48 Million - $2.39 Million	-25,000 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$67.25 - $92.52 $1.58 Million - $2.17 Million	-23,431 Reduced 48.38%	25,000 $2.17 Million
Q1 2021 May 17, 2021	SELL	$72.16 - $117.4 $2.25 Million - $3.65 Million	-31,129 Reduced 39.13%	48,431 $3.99 Million
Q4 2020 Feb 16, 2021	BUY	$38.09 - $100.95 $1.13 Million - $2.98 Million	29,560 Added 59.12%	79,560 $7.23 Million
Q2 2020 Aug 14, 2020	BUY	$20.21 - $35.23 $523,439 - $912,456	25,900 Added 107.47%	50,000 $1.72 Million
Q1 2020 May 15, 2020	BUY	$17.28 - $31.88 $416,448 - $768,308	24,100 New	24,100 $535,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $157M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Moore Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Moore Capital Management, LP with notifications on news.